• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他汀类药物在非酒精性脂肪性肝病中的疗效:系统评价和荟萃分析。

Statins' efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

机构信息

Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece.

First Department of Obstetrics and Gynaecology, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki 56429, Greece.

出版信息

Clin Nutr. 2022 Oct;41(10):2195-2206. doi: 10.1016/j.clnu.2022.08.001. Epub 2022 Aug 8.

DOI:10.1016/j.clnu.2022.08.001
PMID:36081293
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is closely related with the metabolic syndrome and cardiovascular disease. Currently there is no approved medication for NAFLD. Although it has been suggested that statins can be safely used by patients with elevated liver enzymes, their effect on NAFLD has not been clearly defined. The aim of this study is to evaluate the effectiveness of statins on biochemical and histological parameters in patients with NAFLD.

METHODS

We searched PubMed, Web of Science, and SCOPUS for clinical trials and observational studies concerning the effects of statins on the development and treatment of NAFLD, regardless of the type or dosage of statin, the duration of treatment or the methods used for the diagnosis of NAFLD (biopsy or imaging technique) up to November 2021.

RESULTS

We identified 13 studies. Liver function tests and lipid profile were significantly improved. There was a significant decrease in steatosis grade (standardized mean difference, SMD -1.73, 95% CI -2.11 to -1.35; p < 0.00001; I = 98%) and in NAFLD activity score (NAS) (SMD -1.09 (95% CI -1.39 to -0.79; p < 0.00001; I = 93%)).

CONCLUSIONS

Statins effectively decrease liver enzymes and beneficially affect liver histology in NAFLD patients.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)与代谢综合征和心血管疾病密切相关。目前尚无批准用于治疗 NAFLD 的药物。尽管有研究表明升高的肝酶患者可以安全使用他汀类药物,但他汀类药物对 NAFLD 的影响尚未明确。本研究旨在评估他汀类药物对 NAFLD 患者生化和组织学参数的疗效。

方法

我们检索了 PubMed、Web of Science 和 SCOPUS 中关于他汀类药物对 NAFLD 发生和治疗影响的临床试验和观察性研究,无论他汀类药物的类型或剂量、治疗持续时间或用于诊断 NAFLD 的方法(活检或影像学技术)如何,均截止至 2021 年 11 月。

结果

我们共确定了 13 项研究。肝功能试验和血脂谱明显改善。脂肪变性程度评分(标准化均数差,SMD -1.73,95%置信区间-2.11 至-1.35;p<0.00001;I=98%)和 NAFLD 活动评分(NAS)(SMD -1.09,95%置信区间-1.39 至-0.79;p<0.00001;I=93%)均显著降低。

结论

他汀类药物可有效降低肝酶,并对 NAFLD 患者的肝脏组织学产生有益影响。

相似文献

1
Statins' efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis.他汀类药物在非酒精性脂肪性肝病中的疗效:系统评价和荟萃分析。
Clin Nutr. 2022 Oct;41(10):2195-2206. doi: 10.1016/j.clnu.2022.08.001. Epub 2022 Aug 8.
2
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.他汀类药物在治疗和发展非酒精性脂肪性肝病和脂肪性肝炎中的疗效:系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101816. doi: 10.1016/j.clinre.2021.101816. Epub 2021 Oct 2.
3
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.他汀类药物单独使用,或与吡格列酮及其他药物联合使用,用于治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎及相关心血管风险。专家小组声明。
Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4.
4
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.用于非酒精性脂肪性肝病和非酒精性脂肪性肝炎的他汀类药物。
Cochrane Database Syst Rev. 2013 Dec 27;2013(12):CD008623. doi: 10.1002/14651858.CD008623.pub2.
5
Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.他汀类药物:预防和治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎及相关心血管风险的被低估的资产。
Curr Vasc Pharmacol. 2018;16(3):246-253. doi: 10.2174/1570161115666170621082910.
6
The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.他汀类药物在非酒精性脂肪性肝病治疗中的作用。
Curr Pharm Des. 2018;24(38):4587-4592. doi: 10.2174/1381612825666190117114305.
7
Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD).他汀类药物对非酒精性脂肪性肝病(NAFLD)患者肝酶和血脂谱的影响。
J Clin Lipidol. 2024 Jul-Aug;18(4):e501-e508. doi: 10.1016/j.jacl.2024.03.003. Epub 2024 Mar 13.
8
Nonalcoholic fatty liver disease and statins.非酒精性脂肪性肝病与他汀类药物
Metabolism. 2015 Oct;64(10):1215-23. doi: 10.1016/j.metabol.2015.07.003. Epub 2015 Jul 8.
9
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study.剖析他汀类药物使用对脂肪肝疾病的多方面影响:一项多维研究。
EBioMedicine. 2023 Jan;87:104392. doi: 10.1016/j.ebiom.2022.104392. Epub 2022 Dec 8.
10
Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.在疑似非酒精性脂肪性肝病和高心血管风险患者中开具他汀类药物处方:一项基于人群的研究。
Liver Int. 2019 Jul;39(7):1343-1354. doi: 10.1111/liv.14116. Epub 2019 Jun 10.

引用本文的文献

1
Effects of statins on major adverse cardiovascular events, metabolic and inflammatory parameters in patients with hepatitis B virus comorbid with cardiovascular disease.他汀类药物对合并心血管疾病的乙型肝炎病毒患者主要不良心血管事件、代谢和炎症参数的影响。
Cardiovasc Diagn Ther. 2025 Aug 30;15(4):738-754. doi: 10.21037/cdt-2025-63. Epub 2025 Aug 7.
2
Lipoprotein combine index is associated with non-alcoholic fatty liver disease: a 5-year longitudinal cohort study in non-obese Chinese populations with normal lipids.脂蛋白综合指数与非酒精性脂肪性肝病相关:一项针对血脂正常的非肥胖中国人群的5年纵向队列研究。
Front Med (Lausanne). 2025 Aug 15;12:1618576. doi: 10.3389/fmed.2025.1618576. eCollection 2025.
3
Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease.
整合肝脏与心脏健康:降低代谢相关脂肪性肝病患者的心血管风险
World J Cardiol. 2025 Jul 26;17(7):107751. doi: 10.4330/wjc.v17.i7.107751.
4
The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus.他汀类药物治疗与2型糖尿病患者肝脏及胰腺脂肪分数的关联
Diagnostics (Basel). 2025 Feb 10;15(4):426. doi: 10.3390/diagnostics15040426.
5
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢功能障碍相关脂肪性肝病患者血脂异常管理的实用方法
J Lipid Atheroscler. 2025 Jan;14(1):5-29. doi: 10.12997/jla.2025.14.1.5. Epub 2024 Jun 26.
6
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎中心血管风险的降低
Curr Cardiol Rep. 2025 Jan 18;27(1):28. doi: 10.1007/s11886-024-02185-5.
7
Free Cholesterol-Induced Liver Injury in Non-Alcoholic Fatty Liver Disease: Mechanisms and a Therapeutic Intervention Using Dihydrotanshinone I.非酒精性脂肪性肝病中游离胆固醇诱导的肝损伤:机制及二氢丹参酮I的治疗干预
Adv Sci (Weinh). 2025 Jan;12(2):e2406191. doi: 10.1002/advs.202406191. Epub 2024 Nov 19.
8
G-Protein-Coupled Receptor 120 Agonist Mitigates Steatotic and Fibrotic Features Triggered in Obese Mice by the Administration of a High-Fat and High-Carbohydrate Diet.G蛋白偶联受体120激动剂减轻高脂高碳水化合物饮食诱导的肥胖小鼠的脂肪变性和纤维化特征。
ACS Omega. 2024 Jul 10;9(29):31899-31909. doi: 10.1021/acsomega.4c03507. eCollection 2024 Jul 23.
9
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.他汀类药物治疗非酒精性脂肪性肝炎的系统评价:安全性、疗效及作用机制
Molecules. 2024 Apr 19;29(8):1859. doi: 10.3390/molecules29081859.
10
MAFLD as part of systemic metabolic dysregulation.MAFLD作为全身代谢失调的一部分。
Hepatol Int. 2024 Oct;18(Suppl 2):834-847. doi: 10.1007/s12072-024-10660-y. Epub 2024 Apr 9.